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Abstract
In X-linked hypophosphatemia (XLH), serum ﬁbroblast growth factor 23 (FGF23) is increased and results in reduced renal maximum threshold
for phosphate reabsorption (TmP), reduced serum inorganic phosphorus (Pi), and inappropriately low normal serum 1,25 dihydroxyvitamin D
(1,25[OH]2D) concentration, with subsequent development of rickets or osteomalacia. KRN23 is a recombinant human IgG1 monoclonal
antibody that binds to FGF23 and blocks its activity. Up to 4 doses of KRN23 were administered subcutaneously every 28 days to 28 adults with
XLH. Mean standard deviation KRN23 doses administered were 0.05, 0.10 0.01, 0.28 0.06, and 0.48 0.16mg/kg. The mean time to reach
maximum serum KRN23 levels was 7.0 to 8.5 days. The mean KRN23 half-life was 16.4 days. The mean area under the concentration–time curve
(AUCn) for each dosing interval increased proportionally with increases in KRN23 dose. The mean intersubject variability in AUCn ranged from
30% to 37%. The area under the effect concentration–time curve (AUECn) for change from baseline in TmP per glomerular ﬁltration rate, serum
Pi, 1,25(OH)2D, and bone markers for each dosing interval increased linearly with increases in KRN23 AUCn. Linear correlation between serum
KRN23 concentrations and increase in serum Pi support KRN23 dose adjustments based on predose serum Pi concentration.
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Loss-of-function mutations in PHEX cause X-linked
hypophosphatemia (XLH), the most common heritable
form of rickets and osteomalacia. A consequence of the
PHEX mutation is increased expression of FGF23 in
bone.1,2 FGF23 is a hormone that reduces the abundance of
sodium-phosphate cotransporters in the apicalmembrane of
renal proximal tubular cells, resulting in reduced renal
tubular phosphate reabsorption (TmP) and serum phospho-
rus concentration (measured as inorganic phosphorus,
Pi).3–5 FGF23 also decreases renal 1a-hydroxylase activity,
resulting in reduced blood levels of 1,25-dihydroxyvitamin
D (1,25[OH]2D). Thus hypophosphatemia and inappropri-
ately low normal serum 1,25(OH)2D levels for the level of
serum Pi represent 2 characteristic biochemical consequen-
ces of increased FGF23 observed in XLH.6,7
In children with XLH, impaired bone mineralization
results in clinical and radiographic features of rickets,
including lower-extremity bowing, widening of growth
plates, and short stature.7,8 In adults, impairedmineralization
results in osteomalacia and pseudofractures.8 The presence
The Journal of Clinical Pharmacology
© 2015 The Authors. The Journal of
Clinical Pharmacology Published by
Wiley Periodicals, Inc. on behalf
of American College of Clinical
Pharmacology
DOI: 10.1002/jcph.570
1Kyowa Hakko Kirin Pharma Inc., Princeton, NJ, USA
2Indiana University School of Medicine, Indianapolis, IN, USA
3The Methodist Hospital, Houston, TX, USA
4Duke University Medical Center, Durham, NC, USA
5Shriners Hospital for Children, Montreal, Quebec, Canada
6University of California, San Francisco, CA, USA
7Yale Center for X-Linked Hypophosphatemia, Yale University
School of Medicine, New Haven, CT, USA
This is an open access article under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivs License, which
permits use and distribution in any medium, provided the original
work is properly cited, the use is non-commercial and no modiﬁcations
or adaptations are made.
Submitted for publication 29 March 2015; accepted 9 June 2015.
Corresponding Author:
Xiaoping Zhang, PhD, Kyowa Hakko Kirin Pharma Inc., 212 Carnegie
Center, Suite 101, Princeton, NJ 08540 Email: azhang@kyowa-kirin-
pharma.com
Clinicaltrials.gov identiﬁer: NCT01340482
Pharmacokinetics/Pharmacodynamics
2016, 56(2) 176–185
of a reduced mineralization rate in active osteomalacia
results in increased serum and urine concentrations of
biochemical markers of bone turnover.9 Current therapy,
typically with oral calcitriol and phosphate supplements,
targets the biochemical consequences of FGF23 excess and
improves bonemineralization,10,11 but the underlying defect
in renal Pi reabsorption is not corrected, and clinical
responses in bone are highly variable among patients.
Current treatment requires multiple daily doses of medica-
tion and has serious potential complications including
hypercalciuria, hypercalcemia, nephrocalcinosis, nephroli-
thiasis, and parathyroid hyperplasia.12,13 Thus, safer and
more efﬁcacious therapies are needed.14
KRN23 is a recombinant human immunoglobulin (Ig)
G1 monoclonal antibody that binds intact FGF23 (and
FGF23 fragments) at the N-terminal domain. An
antimurine FGF23 antibody binding to FGF23 blocked
biologic activity of FGF23 in mice.12 In hypophospha-
temic Phex-deﬁcient mice, injection of antibody to
murine FGF23 increased both serum Pi and 1,25
(OH)2D concentrations by increasing renal expression
of type IIa sodium-phosphate cotransporters and renal
1a-hydroxylase activity, respectively.15 After serial
injections in these mice, defective mineralization, abnor-
mal cartilage development, and delayed skeletal growth
were improved, conﬁrming that increased FGF23 under-
lies the murine metabolic bone disease and suggests that
inhibition of FGF23 activity may be useful for treating
rickets and osteomalacia in humans with XLH.
Recently, a phase 1 randomized, placebo-controlled,
double-blind trial of KRN23 in adults with XLH
demonstrated that a single intravenous or subcutaneous
dose of KRN23 resulted in prolonged inhibition of FGF23
activity.16,17 Serum Pi, TmP per glomerular ﬁltrate rate
(TmP/GFR), and serum 1,25(OH)2D increased in a dose-
dependent manner, and the half-life of KRN23 given
subcutaneously was 13 to 19 days. The greater than
4-week duration of the Pi effect suggested that subcutane-
ous injection of KRN23 every 4 weeks might be an
effective treatment to increase serum Pi in XLH patients.
Subsequently a phase 1/2 dose-escalation study of repeated
subcutaneous doses of KRN23 at 28-day intervals in adults
with XLH was undertaken to assess the efﬁcacy and safety
of KRN23.18 We report here the secondary objective of
the study, which was to evaluate the pharmacokinetics
(PK), pharmacodynamics (PD), and PK/PD relationships
of serum KRN23 and the biochemical variables.
Methods
Subjects
The study was approved by the relevant local institutional
reviewboards (IRBs):HumanResearch Protection Program,
at Yale University School of Medicine; Human Subjects
Ofﬁce at Indiana University IRB; Copernicus Group IRB at
ResearchTriangle Park inNorthCarolina;Committee for the
Protection of Human Subjects at the University of Texas
Health Science Center Houston; Committee on Human
Research at the University of California San Francisco; and
IRB at McGill University. The study was conducted in
accordance with the International Conference on Harmoni-
zation E6 Good Clinical Practice guidelines and the
Declaration of Helsinki. All subjects provided written
informed consent prior to screening. Adults (18 years of
age) with a clinical diagnosis of XLH, intact serum
FGF23 30pg/mL,19 TmP/GFR < 2.0mg/dL, creatinine
clearance  60mL/min (Cockcroft-Gault equation), and
serum calcium< 10.8mg/dL at screeningwere eligible. Key
exclusion criteria were pregnancy or lactation; historywithin
3 months before screening of major surgery, or receipt of a
monoclonal antibody or a live (attenuated) vaccine. Vitamin
D or vitamin D analogues, calcium or phosphate supple-
ments, or aluminumhydroxidewere not permitted for at least
10 days before screening and throughout the study.
Study Design and Treatment
The dose of KRN23 was calculated using the subject’s
weight on the dosing day. Subjects received a subcutane-
ous dose of KRN23 every 28 days, for up to 4 doses, using
a stepwise escalation of 0.05, 0.1, 0.3, and 0.6mg/kg. For
each subject, the dose was increased based on the fasting
serum Pi concentration on day 26, as follows: if the serum
Pi on day 26 was (1) 2.5mg/dL, the dose increased
1 dose level; (2) >2.5 but 3.5mg/dL, the previous dose
was repeated; (3) >3.5mg/dL, the dose was withheld,
and Pi was retested 28 days later. If the repeat was
(1) 2.5mg/dL, the most recent dose was repeated;
(2) >2.5 but 3.5mg/dL, the dose was reduced 1 dose
level; (3) >3.5mg/dL, the dose was withheld and serum
Pi reevaluated another 28 days later at the discretion of the
investigator and the sponsor. Dosing could be modiﬁed
based on safety observations, including adverse events
and safety laboratory parameters.
Investigational Product
KRN23wasmanufactured, labeled, and packaged in single-
use vials by Kyowa Hakko Kirin Co., Ltd (Tokyo, Japan).
Pharmacokinetic Assessments
Blood samples for measurement of KRN23 concentration
were obtained before each dose, on days 3, 7, 12, 18, and
26 after each dosing and on day 36 after the fourth dose or
at early withdrawal. Serum KRN23 concentrations were
measured at KyowaHakko Kirin California, Inc (La Jolla,
California) using a validated sandwich enzyme-linked
immunosorbant assay (ELISA; data on ﬁle), which
employs an anti-KRN23 mouse monoclonal antibody as
the capture antibody and a biotinylated anti-KRN23
monoclonal antibody as the detection antibody (both were
supplied from Kyowa Hakko Kirin Co., Ltd, Japan).
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Using a streptavidin-alkaline phospha as conjug te to
cata yze the chemiluminescent substrate, the resulting
chemiluminescent light intensity was measured, and the
con entrations of KRN23 were calculated. The calibra-
ion range was 50 to 3000 ng/mL. The lower limit of
quantiﬁcationwas 50 ng/mL. The assay accuracy (relative
error) nd precision (coefﬁcie t of va iation for the mean)
were within acceptance criteria (< 20%) f r a majority
of quali y control samples (94.6%). A small amount of
quality control samples (5.4%) showed relative errors
between 20.7% and 26.7%. Te individual lot of ooled
human serum were spiked with 50 ng/mL KRN23. The
relative error of d tection ange from -11.4% to 7.2%,
whereas all the unspiked individual lots yielded co cen-
trations be w the low limit of quantiﬁcation (50 ng/mL),
conﬁrming the selectivity of the assay.
Detection of Anti-KRN23 A tibodies
Serum samples for anti-KRN23 antibodies were obtained
before each dose a d on day 36 after the fourth dose or at
early withdrawal. Samples were assayed using a validated
electrochemiluminescent (ECL) method. A sequenti
screening algorithm employ d an initial screening assay,
a subseque t immunodepl tion assay, and a neutr lizing
assay a Kyowa Hakko Kiri California, Inc (La Jolla,
California). Testing only proceeded to the subsequ nt
as ay step if the earlier assay result was po itive.
The bridging ECL format for both the screening a d
speciﬁcity c nﬁr ation assays begins with a streptavidin-
coat d plate supplied byMes Scale Discovery (MSD). In
the screening ass y, control and bioan lytical samples are
ﬁrst diluted wi diluent buffer on a 96-well, round-bottom
p lypropylene plate. The , diluted samples are incubated
with a Master Mix containing biotinylated KRN23
capture antibo y) and ruthenylated-KRN23 (detection
antibo y). Following incubation with the labeled drug
mixt re, samples are transferred from the polypropylene
plat to the blocked, str ptavidin-coa MSD plate in
d pl cate and incubated at room temperature w th shaking.
A ter incub ion, unbound material is washed aw y, and
MSD R ad Buffer (ECL substrate) is adde to th wells.
The ECL signal intensity is imme i tely read using an
MSD Sector Imager measuring MSD signal counts, which
is used to evaluate the pres nce of anti-KRN23 antibodies
and assess t e speciﬁcity of any antibodies relative to
KRN23. The speciﬁcity conﬁrmation assay foll w the
same format as the screen ng assay, except that prior to
incubation with the labeled drug mixture, controls and
bioanalytical samples are ﬁrst diluted with buffer contain-
ing immunodepletive antigen (KRN23). Screening assay
c t point was 1.88 for signal ratio.
Pharmacodynamic Assessment
Blood sampl s for pharmacodynamic assessments were
collected at screening, before each dose, on days 3, 7, 12,
18, and 26 fter each dose, and on d y 36 after the last
dos (ﬁ al visit). Biochemical m asurements included
serum Pi, 1,25(OH)2D, 25-hydroxyvita n D (25[OH]D),
creatinine, calcium, and parathyr id hormone (PTH). Pi,
calcium, and creatinine were meas red in the correspond-
ing 2-hour urine collected after an 8-hour fast on the day
bef re the ﬁrst injection nd on days 3, 7, 12, and 26 after
each injection and on day 36 after the last injection.
Calcium, Pi, a d c eatinine were meas red in a 24-hour
urine collected on the d y before the ﬁrst je tion, on
days , 12, and 26 after each injection, and on day 36 after
the last injection. TmP/GFR was c lculated using an
established equation based on glomerular ﬁltration
rate calcula d from creati ine c ear nce.20 Blood and
urine samples for m asurement of bone turnov r markers
were c llected prior to each dose n at the ﬁnal vis t.
Bone for ation markers included serum bone alkaline
phosphat se (BALP), procollagen ty 1, N propeptide
(P1NP), and ost ocalci . B ne resorption markers
included serum carboxy-terminal cross-linked telopeptide
of t pe 1 collagen (CTx), and urine amino-terminal
cross-linked telopeptide of type 1 collagen (NTx).
Serum intact FGF23wasmeasured at baseline using an
ELISA assay (Kainos Laboratories, Japan). All other
biochemical v riables in serum (25[OH]D, 1,25[OH]2D,
PTH, BALP, CTx, osteocal in, Pi, calcium, and creati-
nine) and i urine samples (Pi, c lcium, creatinine, and
NTx) were analyzed by Quest Diagnostic Inc. using
standardiz d automated methodologies.
Pharmacokinetic an Statistical Analysis
Pharmacokinetic (PK) param ters were estimat d using
serum concentration–time data f r all ccum lated doses
from day 1 to the last follow-up visit on day 120.
A noncompartmental analysi m thod was employed to
derive PK p rameters.21 These included area under the
serum concentrati n–time curve fromzero to lastmeasured
concentration (AUClast), rea under the serum concentra-
tion–time curve from zero to inﬁnity (AUCinf), apparent
volume of distribution (V/F), apparent clearance (CL/F),
and terminal elimination h lf-life fter the fourth dosing
interv (t1/2). Pharmacokinetic parameters estimated for
each 28-day dosing interval included area under the serum
concentration–time curve (AUCn), maximum serum
concentration (Cmax,n), predose serum conce tr ti
(Cmin,n), a d time to peak serum concentration (Tmax,n),
where n denotes the number of doses received (1, 2, 3, and
4) up to the me sured dosing interval. Descriptive statistics
w re used for serum KRN23 concentration data and PK
p rameters. All PK par meters were derived using Phoenix
WinNonlin (version 6.3; Pharsight Company, Mountain
View, Califor ia).
Area nder the effect concentra on–time curve for the
cha ge from baseline prior to the ﬁrst dose for TmP, serum
Pi, and 1,25(OH)2D ere c lculated for day 1 to ay 120 of
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Using a streptavidin-alkaline phosphatase conjugate to
catalyze the chemiluminescent substrate, the resulting
chemiluminescent light intensity was measured, and the
concentrations of KRN23 were calculated. The calibra-
tion range was 50 to 3000 ng/mL. The lower limit of
quantiﬁcationwas 50 ng/mL. The assay accuracy (relative
error) and precision (coefﬁcient of variation for the mean)
were within acceptance criteria (< 20%) for a majority
of quality control samples (94.6%). A small amount of
quality control samples (5.4%) showed relative errors
between 20.7% and 26.7%. Ten individual lots of pooled
human serum were spiked with 50 ng/mL KRN23. The
relative error of detection ranged from -11.4% to 7.2%,
whereas all the unspiked individual lots yielded concen-
trations below the low limit of quantiﬁcation (50 ng/mL),
conﬁrming the selectivity of the assay.
Detection of Anti-KRN23 Antibodies
Serum samples for anti-KRN23 antibodies were obtained
before each dose and on day 36 after the fourth dose or at
early withdrawal. Samples were assayed using a validated
electrochemiluminescent (ECL) method. A sequential
screening algorithm employed an initial screening assay,
a subsequent immunodepletion assay, and a neutralizing
assay at Kyowa Hakko Kirin California, Inc (La Jolla,
California). Testing only proceeded to the subsequent
assay step if the earlier assay result was positive.
The bridging ECL format for both the screening and
speciﬁcity conﬁrmation assays begins with a streptavidin-
coated plate supplied byMeso Scale Discovery (MSD). In
the screening assay, control and bioanalytical samples are
ﬁrst diluted with diluent buffer on a 96-well, round-bottom
polypropylene plate. Then, diluted samples are incubated
with a Master Mix containing biotinylated KRN23
(capture antibody) and ruthenylated-KRN23 (detection
antibody). Following incubation with the labeled drug
mixture, samples are transferred from the polypropylene
plate to the blocked, streptavidin-coated MSD plate in
duplicate and incubated at room temperature with shaking.
After incubation, unbound material is washed away, and
MSD Read Buffer (ECL substrate) is added to the wells.
The ECL signal intensity is immediately read using an
MSD Sector Imager measuring MSD signal counts, which
is used to evaluate the presence of anti-KRN23 antibodies
and assess the speciﬁcity of any antibodies relative to
KRN23. The speciﬁcity conﬁrmation assay follows the
same format as the screening assay, except that prior to
incubation with the labeled drug mixture, controls and
bioanalytical samples are ﬁrst diluted with buffer contain-
ing immunodepletive antigen (KRN23). Screening assay
cut point was 1.88 for signal ratio.
Pharmacodynamic Assessments
Blood samples for pharmacodynamic assessments were
collected at screening, before each dose, on days 3, 7, 12,
18, and 26 after each dose, and on day 36 after the last
dose (ﬁnal visit). Biochemical measurements included
serum Pi, 1,25(OH)2D, 25-hydroxyvitaminD (25[OH]D),
creatinine, calcium, and parathyroid hormone (PTH). Pi,
calcium, and creatinine were measured in the correspond-
ing 2-hour urine collected after an 8-hour fast on the day
before the ﬁrst injection and on days 3, 7, 12, and 26 after
each injection and on day 36 after the last injection.
Calcium, Pi, and creatinine were measured in a 24-hour
urine collected on the day before the ﬁrst injection, on
days 3, 12, and 26 after each injection, and on day 36 after
the last injection. TmP/GFR was calculated using an
established equation based on glomerular ﬁltration
rate calculated from creatinine clearance.20 Blood and
urine samples for measurement of bone turnover markers
were collected prior to each dose and at the ﬁnal visit.
Bone formation markers included serum bone alkaline
phosphatase (BALP), procollagen type 1, N propeptide
(P1NP), and osteocalcin. Bone resorption markers
included serum carboxy-terminal cross-linked telopeptide
of type 1 collagen (CTx), and urine amino-terminal
cross-linked telopeptide of type 1 collagen (NTx).
Serum intact FGF23wasmeasured at baseline using an
ELISA assay (Kainos Laboratories, Japan). All other
biochemical variables in serum (25[OH]D, 1,25[OH]2D,
PTH, BALP, CTx, osteocalcin, Pi, calcium, and creati-
nine) and in urine samples (Pi, calcium, creatinine, and
NTx) were analyzed by Quest Diagnostics Inc. using
standardized automated methodologies.
Pharmacokinetic and Statistical Analysis
Pharmacokinetic (PK) parameters were estimated using
serum concentration–time data for all accumulated doses
from day 1 to the last follow-up visit on day 120.
A noncompartmental analysis method was employed to
derive PK parameters.21 These included area under the
serum concentration–time curve fromzero to lastmeasured
concentration (AUClast), area under the serum concentra-
tion–time curve from zero to inﬁnity (AUCinf), apparent
volume of distribution (V/F), apparent clearance (CL/F),
and terminal elimination half-life after the fourth dosing
interval (t1/2). Pharmacokinetic parameters estimated for
each 28-day dosing interval included area under the serum
concentration–time curve (AUCn), maximum serum
concentration (Cmax,n), predose serum concentration
(Cmin,n), and time to peak serum concentration (Tmax,n),
where n denotes the number of doses received (1, 2, 3, and
4) up to the measured dosing interval. Descriptive statistics
were used for serum KRN23 concentration data and PK
parameters. All PK parameters were derived using Phoenix
WinNonlin (version 6.3; Pharsight Company, Mountain
View, California).
Area under the effect concentration–time curve for the
change from baseline prior to the ﬁrst dose for TmP, serum
Pi, and 1,25(OH)2Dwere calculated for day 1 to day 120 of
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treatment or up to the lastmeasured timebeforewithdrawal
(AUEClast) and for each of the 4 dosing intervals (AUEC1,
AUEC2, AUEC3, and AUEC4). Pharmacodynamic (PD)
variables were estimated using SAS software (version 9;
SAS Institute Inc., North Carolina).
Scatterplots were generated to explore PK/PD corre-
lations using AUCn for PK measures and AUECn for
PD measures. Pearson correlation coefﬁcients (R) were
derived from linear regression as appropriate.
During the study conduct, TmP/GFR was manually
derived from a nomogram developed by Walton and
Bijvoet.24 In the analysis, TmP/GFR was calculated from
the following equation20:
TmP=GFRðmg=dLÞ ¼ TRPx½serum phosphorous
ðmg=dLÞ�ðif TRP <¼ 0:86Þ; ð1Þ
TmP=GFRðmg=dLÞ ¼ 0:3xTRP=ð1� 0:8xTRPÞ
x½serum phosphorousðmg=dLÞ�ðif TRP > 0:86Þ;
ð2Þ
where tubular reabsorption of phosphate (TRP) is 1-(2-
hour urine phosphorus [mg/dL])/(serum phosphorus
[mg/dL])� (serum creatinine [mg/dL])/(2-hour urine
creatinine [mg/dL]).
The TmP/GFR values derived from the 2 methods were
compared, but only the calculated results are reported.
Results
Demographics and Baseline Characteristics (Table 1)
KRN23 was administered to 28 subjects. Twenty-six
subjects (92.9%) received 4 doses; 1 subject withdrew
after 3 doses because of injection-site urticaria. One
subject withdrew after 1 dose because of the presence of
moderate to severe preexisting nephrocalcinosis (this
subject did not provide PK samples). The number of
subjects who contributed to the analysis was 27. Eighteen
subjects (64%) were female, and 26 (93%) were white;
mean body weight was 75.6 kg, and mean age was 41.5
years. Mean TmP/GF (1.6� 0.4mg/dL) and serum
Pi (1.9� 0.3mg/dL) were below the normal reference
range. The mean 1,25(OH)2D level (36.6� 14.3 pg/mL)
was within the normal reference range, and only 2
subjects were decreased below the reference range . The
mean 25(OH)D was 25.0� 9.1 ng/mL. Mean PTH was
increased at 74 pg/mL, and mean serum FGF23 was
increased at 91 pg/mL. Mean serum calcium, fasting
2-hour urine calcium /creatinine ratio, and 24-hour urine
calcium excretion were in the normal range. No subject
was hypercalciuric. Mean values for both formation
markers (BALP, osteocalcin, PINP) and resorption
markers (NTx, CTx) were in the normal reference ranges,
although some subjects had increased levels.
KRN23 Doses
All subjects received an initial dose of 0.05mg/kg. For the
seconddose, 26 (96.3%) received0.1mg/kg, and1 remained
at 0.05mg/kg (1 withdrew). For the third dose, 25 subjects
(92.6%) received 0.3mg/kg, 1 continued at 0.05, and 1 at
0.1mg/kg. For the fourth dose, 16 subjects (61.5%) received
0.6mg/kg, 8 continued at 0.3mg/kg, 1 increased from
0.05 to 0.1mg/kg, and 1 from0.1 to 0.3mg/kg (1withdrew).
No subject required dose delay or reduction. The mean total
KRN23 doses administered increased from the ﬁrst to the
fourth dose: 0.05� 0.0, 0.10� 0.01, 0.28� 0.06, and
0.48� 0.16mg/kg for dosing intervals 1, 2, 3, and 4,
respectively.
Pharmacokinetic Results
The mean KRN23 PK exposure (AUCn) increased from
174� 63 after the ﬁrst dose to 2610� 974mg � h/mL after
the fourth dose (Table 2). The AUClast for the 4 dosing
intervals was 4340� 1320mg � h/mL. The extrapolated
part for AUCinf (5240� 1880mg � h/mL) compared with
AUClast was less than 25%. The mean Tmax values were
similar (7.0 to 8.5 days) across the 4 dosing intervals. The
terminal mean t1/2 estimated after the fourth dosing
interval was 16.4 days. Mean serum KRN23 concentra-
tion increased as mean dose increased (Figure 1A). The
mean KRN23 serum PK exposures (log-transformed
Cmax,n, Cmin,n, and AUCn) increased with increased log
dose in a proportional manner, with correlation coef-
ﬁcients (R) of 0.998, 0.993, and 0.998, respectively
(Figure 1B shows AUCn). The mean intersubject
variability in AUCn ranged from 30% to 37%. The
CL/F was 0.186� 0.078mL/h/kg, and the V/F was
98.3� 34.6mL/kg.
Pharmacokinetic and Pharmacodynamic Relationships
Serum Phosphorus. Mean serum Pi concentrations
increased to a maximum on day 7, returned to near
baseline by day 28 after each dose, and increased with
successive doses of KRN23 (Figure 2A). AUECn for
serum Pi was linearly correlated with AUCn for serum
KRN23 (R¼ 0.812; Figure 2B).
TmP/GFR. TmP/GFR values increased to a maximum
on day 7 after each dose, returned to near baseline by day
28, and increased with successive doses of KRN23
(Figure 2C). AUECn for TmP/GFRwas linearly correlated
with serum KRN23AUCn (R¼ 0.822; Figure 2D).
1,25(OH)2D. Serum 1,25(OH)2D concentrations in-
creased to a maximum by day 3 after each dose and then
returned to near baseline values by day 28 (Figure 2E).
AUECn for serum 1,25(OH)2D were linearly correlated
with serum KRN23 AUCn (R¼ 0.666; Figure 2F).
Bone Markers. The AUECn for serum bone formation
markers increased as KRN23 AUCn increased with
moderate correlation. The correlation coefﬁcients (R)
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Using a st e tavidin-alkaline phosphatase conjugate to
catalyze the chemiluminescent substrat , the resulting
chemiluminescent light intensity w s measured, and the
concentrations of KRN23 were calcula ed. The calibra-
tion range was 50 t 3000 ng/mL. The lower limit of
quantiﬁcationwas 50 ng/mL. The assay accuracy (relative
err r) and precision (coefﬁcient of variation for the mean)
were within acceptance crit ria (< 20%) for a majority
of quality control sample (94.6%). A small amount of
quality control samples (5.4%) showed relative errors
b tw en 20.7% a d 26.7%. Ten indivi ual lots of poole
human serum were sp ked with 50 ng/mL KRN23. The
relative error of detection ranged from -11.4% to 7.2%,
whereas all the unspiked individual lots yielded concen-
trations below the low limit of quantiﬁcation (50 ng/mL),
conﬁrming the selectivity of the assay.
Detection of Anti-KRN23 Antibodies
Serum samples for anti-KRN23 antibodies were obtained
before each dose and on day 36 after the fourth dose or at
early withdrawal. Samples were assayed using a validated
electrochemiluminescent (ECL) method. A sequential
screening algorithm employed an initial screening assay,
a subsequent im unodepletion assay, and a ne traliz g
ass y at Kyowa Hakko Kirin California, Inc (La Jolla,
California). Testing only proceeded to the subsequ nt
assay step if he earli r assay r sult wa positive.
The bridging ECL format for both the screening and
speciﬁcity conﬁrmation assays begins with a streptavidin-
coated plate supplied byMeso Scale Discovery (MSD). In
the screening assay, control and bioanalytical samples are
ﬁrst diluted with diluent buffer on a 96-well, round-bottom
polypropylene plate. Then, diluted samples are incubated
with a Master Mix containing biotinylated KRN23
(capture antibody) and ruthenylated-KRN23 (detection
antibody). Following incubation with the labeled drug
mixture, samples are transferred from the polypropylene
plate to the blocked, streptavidin-coated MSD plate in
duplicate and incubated at room temperature with shaking.
After incubation, unbound material is washed away, and
MSD Read Buffer (ECL substrate) is added to the wells.
The ECL signal intensity is immediately read using an
MSD Sector Imager measuring MSD signal counts, which
is used to evaluate the presence of anti-KRN23 antibodies
and assess the speciﬁcity of any antibodies relative to
KRN23. The speciﬁcity conﬁrmation assay follows the
same format as the screening assay, except that prior to
incubation with the labeled drug mixture, controls and
bioanalytical samples are ﬁrst diluted with buffer contain-
ing immunodepletive antigen (KRN23). Screening assay
cut point was 1.88 for signal ratio.
Pharmacodynamic Assessments
Blood samples for pharmacodynamic assessments were
collected at screening, before each dose, on days 3, 7, 12,
18, and 26 after each dose, and on day 36 after the last
dose (ﬁnal visit). Biochemical measurements included
rumPi, 1,25(OH)2D, 25-hydroxyvitaminD (25[OH]D),
creatinine, calcium, and parathyroid hormone (PTH). Pi,
calcium, and creatinine were measured in he correspond-
ing 2-hour urine c llected after an 8-hour fast on th day
before the ﬁrst injection nd on days 3, 7, 12, and 26 after
each injection and on day 36 after the last injection
Calcium, Pi, and creatinine were measured in a 24-hour
urine collected on the day before the ﬁrst injection, on
days 3, 12, and 26 after each injection, and on day 36 after
the last injection. TmP/GFR was calculated usi g an
establish d equation based on glomerular ﬁltration
rate calculated from creatinine clearance.20 Blood and
urine samples for measurement of bone turnover markers
were collected prior to each dose and at the ﬁnal visit.
Bone formation markers included serum bone alkaline
phosphatase (BALP), procollagen type 1, N propeptide
(P1NP), and osteocalcin. Bone resorption markers
included serum carboxy-terminal cross-linked telopeptide
of type 1 collagen (CTx), and urine amino-terminal
cross-linked telopeptide of type 1 collagen (NTx).
Serum intact FGF23wasmeasured at baseline using an
ELISA assay (Kainos Laboratories, Japan). All other
biochemical variables in serum (25[OH]D, 1,25[OH]2D,
PTH, BALP, CTx, osteocalcin, Pi, calcium, and creati-
nine) and in urine samples (Pi, calcium, creatinine, and
NTx) were analyzed by Quest Diagnostics Inc. using
standardized automated methodologies.
Pharmacokinetic and Statistical Analysis
Pharmacokinetic (PK) parameters were estimated using
serum concentration–time data for all accumulated doses
from day 1 to the last follow-up visit on day 120.
A noncompartmental analysis method was employed to
derive PK parameters.21 These included area under the
serum concentration–time curve fromzero to lastmeasured
concentration (AUClast), area under the serum concentra-
tion–time curve from zero to inﬁnity (AUCinf), apparent
volume of distribution (V/F), apparent clearance (CL/F),
and terminal elimination half-life after the fourth dosing
interval (t1/2). Pharmacokinetic parameters estimated for
each 28-day dosing interval included area under the serum
concentration–time curve (AUCn), maximum serum
concentration (Cmax,n), predose serum concentration
(Cmin,n), and time to peak serum concentration (Tmax,n),
where n denotes the number of doses received (1, 2, 3, and
4) up to the measured dosing interval. Descriptive statistics
were used for serum KRN23 concentration data and PK
parameters. All PK parameters were derived using Phoenix
WinNonlin (version 6.3; Pharsight Company, Mountain
View, California).
Area under the effect concentration–time curve for the
change from baseline prior to the ﬁrst dose for TmP, serum
Pi, and 1,25(OH)2Dwere calculated for day 1 to day 120 of
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were 0.373 for BALP (Figure 3A), 0.484 for P1NP
(Figure 3B), and 0.537 for osteocalcin (Figure 3C). The
AUECn for the bone resorption markers increased as
KRN23 AUCn increased. The moderate correlations are
shown by the R values of 0.446 for CTx (Figure 3D) and
0.310 for NTx/creatinine (Figure 3E).
Other Biochemistry Parameters. No meaningful effect of
KRN23 treatment was observed on AUECn for other PD
variables (Figure 4): serum calcium (R¼ 0. 238, Figure 4A),
PTH (R¼ 0.118, Figure 4B), fasting 2-hour calcium/
creatinine ratio (R¼ 0.058, Figure 4C), or 24-hour urine
calcium (R¼ 0.146, Figure 4D). There were also no
meaningful PK/PD correlations observed for the following
PD variables: serum 25(OH)D (R¼ 0.160), creatinine
(R¼ 0.351), ionized calcium (R¼ 0.099); and calcium
(R¼ 0.146), creatinine (R¼ 0.149), and calcium/creatinine
ratio (R¼ 0.291) in 24-hour urine samples (Supplementary
Figure S1).
Table 1. Subject Demographics and Disease Characteristics at Baseline
Characteristica KRN23 Reference Range
Demographics n¼ 27
Age (years) 41.5� 14.0 (19–66) NA
Sex (male/female), n 9/18 NA
Race (white/other), n 26/1 NA
Weight (kg) 75.6� 19.9 (51.3–121.9) NA
Height (cm) 150.1� 12.5 (121.9–170.2) NA
Serum FGF23 (pg/mL), median (range) 91 (36–3520) 8–5422
Serum Pi (mg/dL) 1.9� 0.3 (1.2–2.8) 2.5–4.523
TmP/GFR (mg/dL) 1.6� 0.4 (0.8–2.3) 2.5–4.224
Serum 1,25(OH)2D (pg/mL)
b 36.6� 14.3 (10–62) 15.9–55.625
Serum 25(OH)D, ng/mL 25.0� 9.1 (12–44) 32–10025
Serum total calcium (mg/dL) 9.1� 0.4 (8.5–10.2) 8.5–10.323
Serum PTH (pg/mL), median (range) 74 (38–143) 10–6523
BALP (mg/L) 28.3� 12.8 (8.2–52.4) M: 3.7–20.9
F: 2.9–14.5 (premenopausal)
F: 3.8–22.6 (postmenopausal)23
P1NP (ng/mL) 64.1� 30.7 (11–123) M: 22–87 (18þ years)22
F: 19–83 (premenopausal)23
F: 16–96 (postmenopausal)23
Osteocalcin (ng/mL) 29.3� 17.7 (6.5–95.4) M: 8.0–37023
F: 7.0–38.0 (pre- and postmenopausal
without osteoporosis)23
NTx/creatinine ratio (nmol BCE/mmol) 41.8� 20.3 (12–112) M: 12–99 (18–29 years)23
M: 9–60 (30–59 years)23
M: not established (60þ years)23
F: 4–64 (premenopausal, 18þ years)23
CTx (pg/mL) 752� 389 (214, 1899) M: 87–11200 (18–129 years)23
M: 70–1780 (30–139 years)23
M: 60–1700 (40–149 years)23
M: 87–1345 (50–168 years)23
M: not established (69þ years)23
F: 64–1640 (18–129 years)23
F: 60–1650 (30–139 years)232
F: 40–1465 (40–149 years)23
F: not established (50þ years)232
24-Hour urine calcium (mg/24 hours), median (range) 67 (11–253) M: 50–1300 F: 50–125023
24-Hour urine creatinine (g/24 hours), median (range) 1.13 (0.54–3.01) 0.63–12.5023
2-Hour calcium/creatinine ratio (mg/g creatinine), median (range) 36 (7–192) M: 10–124023 F: 10–132023
24-Hour urine phosphate (mg), median (range) 2244 (1087–4785) M: 1103–14 90323 F: 521–13 67723
aData are presented from baseline and are expressed as mean� standard deviation (range) except where noted.
bn¼ 24 for serum 1,25(OH)2D.
1,25(OH)2D, 1,25-dihydroxyvitamin D; 25(OH)D, 25-hydroxyvitamin D; BALP, bone alkaline phosphatase; F, female; FGF23, ﬁbroblast growth factor 23; PTH,
parathyroid hormone; M, male; NA, not applicable; Pi, serum phosphorus (inorganic); TmP/GFR, renal tubular maximum reabsorption rate of phosphate to
glomerular ﬁltration rate.
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Anti-KRN23-Antibodies
No positive anti-KRN23 antibodies were detected after
KRN23 treatment in any subject from screening assay
testing. Therefore, no further conﬁrmative assay was
needed.
Baseline FGF23 and Serum Pi Response
No apparent correlation between overall serum area under
the effect concentration–time curve (AUEClast) for serum
Pi and baseline intact FGF23 levels was observed
(R¼ 0.0943).
Discussion
KRN23 given subcutaneously in 4 increasing doses every
28 days to adults with XLH, increased TmP, and serum Pi
and 1,25(OH)2D concentrations in aKRN23PK-dependent
manner. The PK exposure to KRN23, asmeasured by Cmax,
n, Cmin,n, andAUCnvalues, increased in a dose-proportional
manner. The V/F for a typical subject weighing 70 kg was
estimated to be 6.9 L, which is slightly larger than the
plasma volume (3–5L26). The mean t1/2 for KRN23
(16.4 days) after multiple-dose KRN23 administration was
similar to themean t1/2 (17.6, 15.1, 13.4, and 18.7 days) after
single subcutaneous administration of KRN23 at doses of
0.1, 0.3, 0.6, and 1.0mg/kg, respectively, indicating that
elimination of KRN23 is not dose dependent. Mean Tmax
values were similar across the 4 dosing intervals and ranged
from 7.0 to 8.5 days, indicating that rate of absorption of
KRN23 after subcutaneous administration was consistent
during every 28-day dosing regimen. Because of intra-
subject dose escalation of KRN23 in this study and a mean
KRN23 t1/2 of 16.4 days, steady-state conditions were not
reached for any dose between 0.1 and 1.0mg/kg.
Administration of a ﬁxed KRN23 dose every 4 weeks for
at least 5 times of the KRN23 t1/2 (ie, approximately 82
days) would be necessary to reach KRN23 steady-state
serum concentrations.
Unlike a standard multiple ascending-dose study
design for a novel monoclonal antibody therapy
(parallel-dose groups),27 the present study employed
an intradose-escalation scheme. The design was based
on the practical reason that the prevalence of XLH is
only 1:20 000.6 For the intradose-escalation design, the
dose–response relationship cannot be analyzed directly.
We therefore used PK exposure (AUCn) and PD
response (AUECn) for the assessment of PK/PD
relationships.
This study demonstrated that increases in TmP/GFR,
serum Pi, and serum 1,25(OH)2D (AUECn) were linearly
correlated with increases in KRN23 PK exposure (AUCn)
following multiple-dose administration of KRN23 in
adults with XLH. TmP/GFR and serum Pi concentrations
reached maximum values as KRN23 concentrations at
Table 2. KRN23 Pharmacokinetic Parameters
Dosing Interval 1 2 3 4
Number of subjects 27 27 27 26
Tmax,n (days) 8.50 � 2.90 (2.98, 14.9) 34 7.04 � 1.71 (3.95, 11.9) 24 7.45 � 3.83 (1.96, 19.9) 27 7.00 � 3.22 (2.87–15.0) 46
Cmax,n (ng/mL) 386 � 145 (193, 688) 38 947 � 307 (356, 1710) 32 2490 � 843 (421, 3950) 34 4750 � 1800 (1030, 8110) 38
Cmin,n (ng/mL) 147 � 53.4 (60.7, 253) 36 364 � 130 (119, 662) 36 1080 � 587 (104, 2560) 54 1470 � 827 (166, 2890) 56
AUCn (mg � h/mL) 174 � 63 (71.6, 316) 36 430 � 127 (156, 685) 30 1220 � 432 (228, 2350) 35 2610 � 974 (572, 4280) 37
Data from all 4 dosing intervals (n¼ 27)
AUClast (mg � h/mL) AUCinf (mg � h/mL) CL/F (mL/h/kg) V/F (mL/kg) t1/2 (days)
4340 � 1320 (1340–6450) 30 5240 � 1880 (1570, 8990) 36 0.186 � 0.0780 (0.0835, 0.472) 42 98.3 � 34.6 (51.2, 21.2) 35 16.4 � 5.83 (5.58, 29.5) 35
Mean� standard deviation (min, max) CV% is reported.
Figure 1. Mean serumKRN23 concentration over time (A) and dose proportionality betweenmean log KRN23AUCn and mean log dose during the 4
dosing intervals (B). Error bars represent standard deviation (SD). The mean� SD dose was 0.05� 0.0, 0.10� 0.01, 0.28� 0.06, and 0.48� 0.16mg/kg
for dosing intervals 1, 2, 3, and 4, respectively. N¼ 27 for dosing intervals 1 to 3 and n¼ 26 for dosing interval 4.
6 The Journal of Clinical Pharmacology / Vol XX No XX 2015
Using a streptavidin-alkaline phosphatase conjugate to
catalyze the chemiluminescent substrate, the resulting
chemiluminescent light intensity was measured, and the
concentrations of KRN23 were calculated. The calibra-
tion range was 50 to 3000 ng/mL. The lower limit of
quantiﬁcationwas 50 ng/mL. The assay accuracy (relative
erro ) and precision (coefﬁcient of variation for the mean)
were within acceptance criteria (< 20%) for a majority
of quality control samples (94.6%). A small amount of
quality control samples (5.4%) showed relative errors
between 20.7% and 26.7%. Ten individual lots of pooled
human serum were spiked with 50 ng/mL KRN23. The
relative error of detection ranged from -11.4% to 7.2%,
whereas all the unspiked individual lots yielded concen-
trations below the low limit of quantiﬁcation (50 ng/mL),
conﬁrming the selectivity of the assay.
Detection of Anti-KRN23 Antibodies
Serum samples for anti-KRN23 antibodies were obtained
before each dose and on day 36 after the fourth dose or at
early withdrawal. Samples were assayed using a validated
electrochemiluminescent (ECL) method. A sequential
screening algorithm employed an initial screening assay,
a subsequent immunodepletion assay, and a neutralizing
assay at Kyowa Hakko Kirin California, Inc (La Jolla,
California). Testing only proceeded to the subsequent
assay step if the earlier assay result was positive.
The bridging ECL format for both the screening and
speciﬁcity conﬁrmation assays begins with a streptavidin-
coated plate supplied byMeso Scale Discovery (MSD). In
the screening assay, control and bioanalytical samples are
ﬁrst diluted with diluent buffer on a 96-well, round-bottom
polypropylene plate. Then, diluted samples are incubated
with a Master Mix containing biotinylated KRN23
(capture antibody) and ruthenylated-KRN23 (detection
antibody). Following incubation with the labeled drug
mixture, samples are transferred from the polypropylene
plate to the blocked, streptavidin-coated MSD plate in
duplicate and incubated at room temperature with shaking.
After incubation, unbound material is washed away, and
MSD Read Buffer (ECL substrate) is added to the wells.
The ECL signal intensity is immediately read using an
MSD Sector Imager measuring MSD signal counts, which
is used to evaluate the presence of anti-KRN23 antibodies
and assess the speciﬁcity of any antibodies relative to
KRN23. The speciﬁcity conﬁrmation assay follows the
same format as the screening assay, except that prior to
incubation with the labeled drug mixture, controls and
bioanalytical samples are ﬁrst diluted with buffer contain-
ing immunodepletive antigen (KRN23). Screening assay
cut point was 1.88 for signal ratio.
Pharmacodynamic Assessments
Blood samples for pharmacodynamic assessments were
collected at screening, before each dose, on days 3, 7, 12,
18, and 26 after each dose, and on day 36 after the last
dose (ﬁnal visit). Biochemical measurements included
serum Pi, 1,25(OH)2D, 25-hydroxyvitaminD ( 5[OH]D),
creatinine, calcium, and parathyroid hormone (PTH). Pi,
calcium, and creatinine were measured in the correspond-
ing 2-hour urine collected after an 8-hour fast on the day
before the ﬁrst injection and on days 3, 7, 12, and 26 after
each injection and on day 36 after the last injection.
Calcium, Pi, and creatinine were measured in a 24-hour
urine collected on the day before the ﬁrst injection, on
days 3, 12, and 26 after each injection, and on day 36 after
the last injection. TmP/GFR was calculated using an
established equation based on glomerular ﬁltration
rate calculated from creatinine clearance.20 Blood and
urine samples for measurement of bone turnover markers
were collected prior to each dose and at the ﬁnal visit.
Bone formation markers included serum bone alkaline
phosphatase (BALP), procollagen type 1, N propeptide
(P1NP), and osteocalcin. Bone resorption markers
included serum carboxy-terminal cross-linked telopeptide
of type 1 collagen (CTx), and urine amino-terminal
cross-linked telopeptide of type 1 collagen (NTx).
Serum intact FGF23wasmeasured at baseline using an
ELISA assay (Kainos Laboratories, Japan). All other
biochemical variables in serum (25[OH]D, 1,25[OH]2D,
PTH, BALP, CTx, osteocalcin, Pi, calcium, and creati-
nine) and in urine samples (Pi, calcium, creatinine, and
NTx) were analyzed by Quest Diagnostics Inc. using
standardized automated methodologies.
Pharmacokinetic and Statistical Analysis
Pharmacokinetic (PK) parameters were estimated using
serum concentration–time data for all accumulated doses
from day 1 to the last follow-up visit on day 120.
A noncompartmental analysis method was employed to
derive PK parameters. 1 These included area under the
serum concentration–time curve fromzero to lastmeasured
concentration (AUClast), area under the serum concentra-
tion–time curve from zero to inﬁnity (AUCinf), apparent
volume of distribution (V/F), apparent clearance (CL/F),
and terminal elimination half-life after the fourth dosing
interval (t1/2). Pharmacokinetic parameters estimated for
each 28-day dosing interval included area under the serum
concentration–time curve (AUCn), maximum serum
concentration (Cmax,n), predose serum concentration
(Cmin,n), and time to peak serum concentration (Tmax,n),
where n denotes the number of doses received (1, 2, 3, and
4) up to the measured dosing interval. Descriptive statistics
were used for serum KRN23 concentration data and PK
parameters. All PK parameters were derived using Phoenix
WinNonlin (version 6.3; Pharsight Company, Mountain
View, California).
Area under the effect concentration–time curve for the
change from baseline prior to the ﬁrst dose for TmP, serum
Pi, 1,25(OH)2Dwere calculated for day 1 to day 120 of
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about the same time after each dose, and their levels
increased and decreased in parallel. The direct relation-
ship between serum KRN23 concentration and serum
Pi increase reﬂects the dose-dependent blocking action of
the antibody on renal phosphate reabsorption and supports
dose adjustment of KRN23 based on peak and trough
serum Pi concentrations.
In the present study, the body weight–based dose was
employed instead of a ﬁxed dose, which is usually
used for subcutaneous route of administration.28 As the
study design was an intradose escalation, the body
weight–based dosing strategy was employed to minimize
variability.
In the present analysis, TmP/GFR values were both
manually read using a nomogram24 and calculated using
an equation.20 The values derived from 2 methods
resulted in a linear correlation with an R of 0.996.
Thus, the equation20 that is easier to perform than manual
reading may be used in future clinical trials.
The increased serum 1,25(OH)2D levels observed in
the study might have been expected to increase
intestinal calcium absorption (not measured) and
potentially increase serum calcium concentration and
urine calcium excretion. However, serum calcium
and urine calcium did not change, and there were no
correlations between serum KRN23 concentrations and
serum and urine calcium changes. This might suggest
that the increased absorbed calcium was deposited in
bone, a strong likelihood in the setting of osteomalacia
in XLH patients.
Figure 2. Pharmacodynamic (PD) proﬁles over 4 dosing intervals (left) and relationship of pharmacokinetic (PK) and PD parameters (right). (A and B)
Serum Pi; (C and D) TmP/GFR; (E and F) 1,25(OH)2D. AUCn, area under the KRN23 serum concentration–time curve; AUECn, area under the effect
concentration–time curve for PD change from baseline during interval n (n¼ 1, 2, 3, or 4); R, Pearson correlation coefﬁcient.
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The increases in serum 1,25(OH)2D may also have
been expected to decrease the increased serum PTH levels
resulting from secondary hyperparathyroidism present in
many of the patients. However, no change in serum PTH
was observed, possibly because resolution of secondary
hyperparathyroidism takes considerably more time than
that evaluated in this study.
The increase in both bone formation and bone
resorption markers and the moderate correlation
between their serum AUECn and serum KRN23
AUCn is of great interest because it implies an indirect
effect of KRN23 intervention on bone turnover. As a
group, the patients had normal levels of bone biomark-
ers at baseline, although several subjects had clearly
increased levels, probably indicating varying degrees of
osteomalacia. An initial paradoxical rise in both
formation and resorption bone biomarkers was seen in
patients with hypophosphatemic osteomalacia on start-
ing treatment with the active vitamin D analogue,
1-alpha hydroxy vitamin D3, and phosphate supple-
ments with the bone markers returning to normal
reference range after several months of successful
treatment.9 The paradoxical initial increase is generally
considered to be due to osteoblast stimulation of bone
turnover. Thus, the rise in biomarkers with KRN23
suggests that the increase in serum phosphate and 1,25
(OH)2D was starting to heal the osteomalacia.
Overall PK/PD results after multiple doses of KRN23
subcutaneous administration conﬁrmed the PK/PD rela-
tionships observed after single-dose KRN23 subcutaneous
Figure 3. Relationship of pharmacokinetic and bone marker change from baseline. (A) BALP; (B) P1NP; (C) Osteocalcin; (D) CTx; (E) NTx/
creatinine. AUCn, area under the KRN23 serum concentration–time curve; AUECn, area under the effect concentration–time curve for bone marker
change from baseline during interval n (n¼ 1, 2, 3, or 4); R, Pearson correlation coefﬁcient.
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Using a streptavidin-alkaline phosphatase conjugate to
catalyze the chemiluminescent substrate, the resulting
chemiluminescent light intensity was measured, and the
concentrations of KRN23 were calculated. The calibra-
tion range was 50 to 3000 ng/mL. The lower limit of
quantiﬁcationwas 50 ng/mL. The assay accuracy (relative
error) and precision (coefﬁcient of variation for the mean)
were within acceptance criteria (< 20%) for a majority
of quality control samples (94.6%). A small amount of
quality control samples (5.4%) showed relative errors
between 20.7% and 26.7%. Ten individual lots of pooled
human serum were spiked with 50 ng/mL KRN23. The
relative error of detection ranged from -11.4% to 7.2%,
whereas all the unspiked individual lots yielded concen-
trations below the low limit of quantiﬁcation (50 ng/mL),
conﬁrming the selectivity of the assay.
Detection of Anti-KRN23 Antibodies
Serum samples for anti-KRN23 antibodies were obtained
before each dose and on day 36 after the fourth dose or at
early withdrawal. Samples were assayed using a validated
electrochemiluminescent (ECL) method. A sequential
screening algorithm employed an initial screening assay,
a subsequent immunodepletion assay, and a neutralizing
assay at Kyowa Hakko Kirin California, Inc (La Jolla,
California). Testing only proceeded to the subsequent
assay step if the earlier assay result was positive.
The bridging ECL format for both the screening and
speciﬁcity conﬁrmation assays begins with a streptavidin-
coated plate supplied byMeso Scale Discovery (MSD). In
the screening assay, control and bioanalytical samples are
ﬁrst diluted with diluent buffer on a 96-well, round-bottom
polypropylene plate. Then, diluted samples are incubated
with a Master Mix containing biotinylated KRN23
(capture antibody) and ruthenylated-KRN23 (detection
antibody). Following incubation with the labeled drug
mixture, samples are transferred from the polypropylene
plate to the blocked, streptavidin-coated MSD plate in
duplicate and incubated at room temperature with shaking.
After incubation, u bound material is washed way, nd
MSD Read Buffer (ECL substrat ) is added to the wells.
The ECL signal intensity is immediately read using a
MSD Sector Imager measuring MSD signal counts, which
is used to evaluate the presence of anti-KRN23 antibodies
and assess the speciﬁcity of any antibodies relative to
KRN23. The speciﬁci y conﬁrmation assay follows the
same format the screening assay, except th t prior to
incubati with the labeled drug mixture, controls and
ioanalytical samples are ﬁrst diluted with b ffer contain-
ing immunodeplet ve antigen (KRN23). Screening assay
cut point was 1.88 for sig al ratio.
Pharmacodynamic Assessments
Blood sampl s for ph rmacodynamic ssessm nts were
collected at screening, before each dose, on days 3, 7, 12,
18, and 26 after each dose, and on day 36 after the last
dose (ﬁnal visit). Biochemical measurements included
serum Pi, 1,25(OH)2D, 25-hydroxyvitaminD (25[OH]D),
creatinine, calcium, and parathyroid hormone (PTH). Pi,
calcium, and creatinine were measured in the correspond-
ing 2-hour urine collected after an 8-hour fast on the day
before the ﬁrst injection and on days 3, 7, 12, and 26 after
each injection and on day 36 after the last injection.
Calcium, Pi, and creatinine were measured in a 24-hour
urine collected on the day before the ﬁrst injection, on
days 3, 12, and 26 after each injection, and on day 36 after
the last injection. TmP/GFR was calculated using an
established equation based on glomerular ﬁltration
rate calculated from creatinine clearance.20 Blood and
urine samples for measurement of bone turnover markers
were collected prior to each dose and at the ﬁnal visit.
Bone formation markers included serum bone alkaline
phosphatase (BALP), procollagen type 1, N propeptide
(P1NP), and osteocalcin. Bone resorption markers
included serum carboxy-terminal cross-linked telopeptide
of type 1 collagen (CTx), and urine amino-terminal
cross-linked telopeptide of type 1 collagen (NTx).
Serum intact FGF23wasmeasured at baseline using an
ELISA assay (Kainos Laboratories, Japan). All other
biochemical variables in serum (25[OH]D, 1,25[OH]2D,
PTH, BALP, CTx, osteocalcin, Pi, calcium, and creati-
nine) and in urine samples (Pi, calcium, creatinine, and
NTx) were analyzed by Quest Diagnostics Inc. using
standardized automated methodologies.
Pharmacokinetic and Statistical Analysis
Pharmacokinetic (PK) parameters were estimated using
serum concentration–time data for all accumulated doses
from day 1 to the last follow-up visit on day 120.
A noncompartmental analysis method was employed to
derive PK parameters.21 These included area under the
serum concentration–time curve fromzero to lastmeasured
concentration (AUClast), area under the serum concentra-
tion–time curve from zero to inﬁnity (AUCinf), apparent
volume of distributio (V/F), pparent clearance (CL/F),
and termin l elimination half-life after the fourth dosing
interval (t1/2). Pharmacokinetic parameters estimated for
each 28-day dosing interval included rea under the ser m
concentration–time curve (AUCn), maximum serum
concentration (Cmax,n), predose serum conce tration
(Cmin,n), and time to peak serum c centration (Tmax,n),
where n denotes the number of doses rec ived (1, 2, 3, and
4) up to the measured dosing interval. Descriptive statistics
were used for erum KRN23 concentration data and PK
parameters. All PK param ters were derived using Phoenix
WinNonlin (versio 6.3; Pharsight C pany, Mountain
View, Ca ifornia).
Area under the effect c centration–tim curve fo the
change fr m bas line p ior to the ﬁrst dose for TmP, serum
Pi, and 1,25(OH)2Dwere calculated for day 1 to day 120 of
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administration,15,16 and further support the mechanism of
action for KRN23 to block FGF23 activity.
In conclusion, the effects of KRN23 administered
subcutaneously at 28-day intervals on serum Pi, TmP/
GFR, and serum 1,25(OH)2D levels were sustained after
each dose. There was also stimulation of bone turnover.
PK dose proportionality and the linear PK/PD relationship
between serum KRN23 and Pi concentrations support
adjusting the KRN23 dose based on serum Pi levels.
KRN23 is a promising treatment for XLH patients.
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Using a streptavidin-alkaline pho phatase conjugate to
catalyz the chemilumi escent substrate, the resulting
chemiluminesc nt light intensity was measure , and the
concentrations of KRN23 were calculat d. The calibra-
tion range was 50 to 3000 ng/mL. The lower limit of
quantiﬁcationwas 50 ng/mL. The assay accuracy (relative
error) and precision (coefﬁcient of variation for the mean)
were within acceptance criteria (< 20%) for a majority
of quality control samples (94.6%). A small amount of
quality con rol samples (5.4%) showed relative errors
between 20.7% and 26.7%. Ten individual lots of pooled
human serum were spiked with 50 ng/mL KRN23. The
relative error of detection ranged from -11.4% to 7.2%,
whereas all the unspiked individual lots yielded concen-
trations below the low limit of quantiﬁcation (50 ng/mL),
conﬁrming the selectivity of the assay.
Detection of Anti-KRN23 Antibodies
Serum samples for anti-KRN23 antibodies were obtained
before each dose and on day 36 after the fourth dose or at
early withdrawal. Samples were assaye using a va idated
electrochemiluminescent (ECL) method. A sequenti l
screening algorithm employed an initial screening assay,
a subsequent immunodepletion assay, and a neutralizing
assay at Kyowa Hakko Kirin California, Inc (La Jolla,
California). Testing only proceeded to t subsequent
assay step if the earlier assay result was positive.
The bridging ECL format for both the screening and
speciﬁcity conﬁrmation assays begins with a streptavidin-
coated plate supplied byMeso Scale Discovery (MSD). In
the sc e ning assay, cont ol and bioanalytical samples are
ﬁrst diluted with diluent buffer on a 96-well, round-bottom
polypropylene plate. Then, diluted samples are incubated
with a Master Mix containing biotinylated KRN23
(capture antibody) and ruthenylated-KRN23 (detection
antibody). Following incubation with the labeled drug
mixture, samples are transferred from the polypropylene
plate to the blocked, streptavidin-coated MSD plate in
duplicate and incubated at room temperature with shaking.
After incubation, unbound material is washed away, and
MSD Read Buffer (ECL substra e) is added to the wells.
The ECL signal intensity is immediately read using an
MSD Sector Imager measuring MSD signal counts, which
is used to evaluate the presence of anti-KRN23 antibodies
and assess the speciﬁcity of any antibodies relative to
KRN23. The spec ﬁcity conﬁrmation assay follows the
same f rm t as the scr ening assay, except that prior to
incubation with the labeled drug mixture, controls and
bioanalytical samples are ﬁrst diluted with buffer contain-
ing immunodepletive antigen (KRN23). Screening assay
cut point was 1.88 for signal ratio.
Pharmacodynamic Assessments
Blood samples for pharmacodynamic assessments were
collected at screening, before each dose, on days 3, 7, 12,
8, and 26 after e ch dose, and on day 36 after the last
dose (ﬁnal visit). Biochemical measurements included
serum Pi, 1,25(OH)2D, 25-hydroxyvitaminD (25[OH]D),
creatinine, calcium, and parathyroid hormone (PTH). Pi,
calcium, and creatinine were measured in the correspond-
ing 2-hour urine collected after an 8- our fast on the day
before the ﬁrst injection and on days 3, 7, 12, and 26 after
each injection and on day 36 after the last injection.
Calcium, Pi, and creatinine were measured in a 24-hour
urine collected on the day before the ﬁrst injection, on
days 3, 12, and 26 after each injection, and on day 36 after
the last injection. TmP/GFR was calculated using an
established equation based on glomerular ﬁltration
rate calculated from creatinine clearance.20 Blood and
urine samples for measurement of bone turnover markers
were collected prior to each dose and at the ﬁnal visit.
Bone formation markers included serum bone alkaline
phosphatase (BALP), procollagen type 1, N propeptide
(P1NP), and osteocalcin. Bone resorption markers
included serum carboxy-terminal cross-linked telopeptide
of type 1 collagen (CTx), and urine amino-terminal
cross-linked telopeptide of type 1 collagen (NTx).
Serum intact FGF23wasmeasured at baseline using an
ELISA assay (Kainos Laboratories, Japan). All other
biochemical variables in seru (25[OH]D, 1,25[OH]2D,
PTH, BALP, CTx, osteocalcin, Pi, calcium, and creati-
nine) and in urine samples (Pi, calcium, creatinine, and
NTx) were analyzed by Quest Diagnostics Inc. using
standardized automated methodologies.
Pharmacokinetic and Statistical Analysis
Pharmacokinetic (PK) parameters were estimated using
serum concentration–time data for all accumulated doses
from day 1 to the last follow-up visit on day 120.
A noncompartmental analysis method was employed to
derive PK parameters.21 These i cluded ar a under the
serum concentration–time curve fro zero to lastmeasured
concentration (AUClast), area under the serum concentra-
tion–time curve from zero to inﬁnity (AUCinf), apparent
volume of distribution (V/F), apparent clearance (CL/F),
and terminal elimination half-life after the fourth dosing
interval (t1/2). Pharmacokinetic parameters estimated for
each 28-day dosing interval included area under the serum
concentration–time curve (AUCn), maximum serum
concentration (Cmax,n), predose serum concentration
(Cmin,n), and time to peak serum concentration (Tmax,n),
where n denotes the number of doses received (1, 2, 3, and
4) up to the measured dosing interval. Descriptive statistics
were used for serum KRN23 concentration data and PK
parameters. All PK parameters were derived using Phoenix
WinNonlin (version 6.3; Pharsight Company, Mountain
View, California).
Area under the effect concentration–time curve for the
change from baseline prior to the ﬁrst dose for TmP, serum
Pi, and 1,25(OH)2Dwere calculated for day 1 to day 120 of
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